Drug Profile
AdRasN17
Alternative Names: AdRasN17 gene therapyLatest Information Update: 11 Nov 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Gene therapies
- Mechanism of Action Ras gene inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Coronary artery restenosis
Most Recent Events
- 06 Dec 2000 Preclinical development for Coronary artery restenosis in USA (Unknown route)